Alexandria Real Estate Equities (ARE) Q3 2026 earnings call transcript

Thank you, and good afternoon, everyone. This conference call contains forward-looking statements within the meaning of the federal securities laws. The company's actual results might differ materially from those projected in the forward-looking statements. Additional information concerning factors that could cause results to differ materially from those in the forward-looking statements is contained in the company's periodic reports filed with the Securities and Exchange Commission.

And now I'd like to turn the call over to Joel Marcus, Executive Chairman and Founder. Please go ahead, Joel.

Thank you, Paul, and good day, everybody, and welcome to Alexandria's third quarter earnings call. First of all, I want to thank each and every member individually and collectively of the Alexandria team for a very solid third quarter 2026. As a family team, we've impacted the lives of countless patients here in the United States and around the world. And thank you for your commitment to the life science sector through real estate venture capital that has really transformed the impact on the growth and success of this. amazing industry. And with that, I'd like to highlight a couple of key thoughts before turning it over to Mark Benda, our Chief Financial Officer, to recap the quarter. First of all, under the category of demand and leasing, we had a solid third quarter leasing over 1.2 million square feet.

Notably, we had a weighted average lease term of about 11 years, which is pretty great, and we had the second highest filling of vacant space in the company's history. 74% of our leasing was existing tenants. We do have the largest life science tenant base in the industry, and it was quite well balanced, except for public biotech, but we expect that to contribute, importantly, to fourth quarter projected leasing of about 1.25 million square feet.

Helpful was the defeat of the cap on indirect costs, an issue that we have talked about many times, and that circuit court essentially beating off that cap helped drive institutional demand in leasing this quarter. One interesting indicator, people always wonder about the potential for public biotech health. Rather than the XBI, I think people should look at what's called the BBC ETF, about 129 stocks, 93% of which are clinical stage, which I think reflect the public biotech sector probably more realistically.

Clinical stage biotech valuations still remain well below historical averages. There's been a good contribution this quarter from advanced technology companies as they're very attracted to our mega campuses for their recruitment and retention, as well as our wonderful infrastructure that is quite well suited to their businesses. For 2027, we have, I think, a very strong 60-plus percent of the 1.37 million square feet of lease rolls with expected downtime. We're engaged with specific tenants, and that's very good at this stage.

Moving on to the capital plan, and Mark will have a lot to say about that. We had very successful, very solid progress in the third quarter and through this earnings call, including the hybrid notes, raising a billion dollars in a very unique and very timely REIT debut for this instrument. And it's useful to note that over $160 billion of hybrid notes in the U. S. trade and get 50% equity credit from the rating agencies. We just recently closed a $475 million joint venture at Campus Point with our continuing control of that core mega campus. Our ownership will grow back over 50% as we fund our Novartis Build the Suit.

And on the Bristol-Myers space that's coming back to us on that campus, about 250-plus thousand square feet rolling next year, 2027, I'm pleased to say we're in advanced negotiations and expect to resolve on very favorable terms almost 200,000 square feet of that.

Moving on to the balance sheet and leverage. Importantly, we expect to hit our year-end guidance of 5.6 to 6.2 times. We closed and extended our $5 billion credit line. We have the longest weighted average remaining debt term of all S&P 500 REITs at over 11.5 years. We have just $350 million of debt maturities next year. And then I'd like to refer everybody to pages XB and XVI of the supplement, showing our very significant progress in reducing cap interest as we transition from a decade life science bull run and COVID rocket ship era when our leasing went up 4X overnight. and that was led by historic development growth. That transition is never simple and takes a fair amount of time, but we're well into it.

Significant reductions are also noted on those pages in non-income producing assets as a percentage of gross assets, which is very, very good, and our ARR from non-core assets versus a percentage of total ARR overall, especially from the mega-campus' continuing decline. On the path forward, which we'll have more to say at our December 2 investor day, we'll talk about 2027 and beyond. In the interim, we're laser focused on many items, but including most importantly moving leased vacant space into operations as rapidly as possible, leasing currently vacant space, space, future rollovers, and redevelopment space as rapidly as possible in focusing our CapEx on re-leasing with the path to NOI.

We're also heavily focused on continuing dispositions of land and non-core assets, especially focused on those without a reasonable path to NOI, and we've certainly culled our asset base considerably at this point. And then finally, execution of our capital plan to ensure we continue to achieve our leverage targets. And with that, let me turn it over to Mark for a highlight of this third quarter. Mark?

Thank you, Joel. This is Mark Binda. Good afternoon, everyone. Congratulations to the entire Alexandria team for continued solid execution during the quarter, including the five key accomplishments. First, great progress on the funding plan with $1.7 billion of capital completed since June 30th, including $234 million of dispositions of land and non-core assets completed, a $475 million joint venture completed in October, and $1 billion of junior subordinated notes, which received 50% equity credit from key rating agencies.

Second, completed and pending dispositions and sales of partial interest aggregate $2.6 billion and exceed the midpoint of our $1.9 billion target by $720 million, which gives us the opportunity to defer some proceeds into 2027.

Third, we had solid leasing volume for the quarter of 1.2 million square feet, which was the highest total volume in the last seven quarters and included 451,000 square feet of leasing from previously vacant space, which was the second largest quarterly total in company history.

Fourth, we continue to monetize the pipeline through deliveries of development and redevelopment space of 529,000 square feet during the quarter, providing $40 million of incremental annual net operating income and through successful resolution of projects under evaluation, including 421 Park, which is under contract to sell, and our 311 Arsenal project, which has around half of the building leased or under negotiation, primarily with advanced technology tenants.

And fifth, we continue to manage general and administrative expenses prudently, as our G&A expenses as a percentage of net operating income are almost half the S&P 500 REIT average. FFO per share diluted as adjusted was $1.54 for 3Q26, and we reaffirmed the midpoint of our guidance for 2026 FFO per share diluted as adjusted at $6.40, while tightening the range to plus or minus two cents.

Leasing volume for the quarter was solid at 1,236,000 square feet and represented the largest total volume in the last seven quarters. Five key items to highlight on leasing activity.

First, leasing a previously vacant space of 451,000 square feet was up significantly over the last several quarters and represented the second largest quarterly amount in company history. Second, leasing with public biotech remained muted, representing only 1.1% of total leasing volume for the quarter and remains a future potential catalyst. And third, we expect continued positive leasing momentum into the fourth quarter with an early estimate of 1.25 million square feet.

Fourth, we continue to outperform the broader markets on leasing. For our three largest markets, our share of the leasing represented 1.7 times our total share of the lab market over the last four quarters, driven by our high-quality assets, mega-campus model, operational excellence, and brand. And fifth, with respect to life science tenants in the market, after two consecutive quarters of high growth, we observed a modest 5% decline in the list of total tenants in the market across all our markets.

Greater Boston and San Francisco had moderate gains, and San Diego had a moderate decline. Declines are typically caused by the demand converting to leases without an equal number of new tenants to backfill the list. Initial free rent concessions remained elevated at two months per year of term for the trailing 12 months ended 3Q26, really driven by one large non-life science lease signed in Research Triangle.

Excluding this lease, free rent concessions would have been significantly lower at 1.1 months per annum. Tenant improvements and leasing commissions on renewed and releasing space were modest during the quarter. In fact, as a percentage of total rent, they were 7.4%, which is the lowest percentage over the last 10 quarters.

Occupancy at the end of 3Q26 was 87.1%, up 20 basis points from the prior quarter and in line with our guidance for year-end 2026 occupancy, which remained unchanged. We continue to significantly outperform on occupancy in our largest three markets, ranging from 6% to 12% higher than those broader markets. Bolstered by solid new leasing during the past few quarters, we have leases aggregating 1.3 million square feet, which will add 3.7% to occupancy over time and are expected to commence in June 2027 on average with expected annual rental revenue of $52 million.

We did not make any changes to our guidance for occupancy, rental rate changes on lease renewals or releasing of space, or same property performance. Same property net operating income was down 6.7% and 2.8% on a cash basis for the quarter. The overall decline for 3Q26 same property performance was primarily driven by lower occupancy in 2026. The recent quarter represented an improvement compared to the prior quarter performance of 3.9% and 5.8% on a cash basis, primarily related to slightly better occupancy dynamics in the comparative same property pool and changes to the same property pool driven by certain properties that were designated for health for sale during the quarter.

Despite current challenges in the life science real estate market, we continue to benefit from a high-quality tenant base, with 57% of our annual rental revenue coming from investment-grade or publicly traded large-cap tenants, long remaining lease terms of 7.7 years, average rent steps approaching 3% on 97% of our leases, and strong adjusted EBITDA margins of 65% for the quarter.

We continue to focus on the successful reduction in management of general and administrative expenses. We remain on track with our guidance range of $134 to $154 million for 2026, And our trailing 12-month G&A is a percentage of net operating income through 3Q26 of 7.5% is almost half of the average for all S&P 500 REITs over the last few years of 14.3%. Realized gains included in FFO per share diluted as adjusted from our venture investments were million for 3Q26 and million for the first three quarters of 2026 We lowered our guidance range for realized investment gains by $10 million at the midpoint from $75 million to $65 million due to certain transactions being pushed out into 2027.

We expect average real estate basis capitalized to reach a bottom for 2026 in the fourth quarter, ranging from $3.4 billion to $4.9 billion, which is a 40% to 60% decline from the basis that was capitalized for all of 2025. This is generally consistent with a significant 40% reduction in non-income producing assets as a percentage of gross assets, which has declined from 20% at the end of 2024 to 12% as of 3Q26. Capitalized interest for 3Q26 was $62.9 million. It was down $11 million from the prior quarter, primarily driven by significant deliveries from the pipeline, coupled with redevelopment projects that reached milestones and were paused.

We expect a further decline in capitalized interest in the fourth quarter, driven by two large projects designated as held for sale at September 30th, coupled with significant deliveries from the pipeline in 3Q26, including the 199,000-square-foot delivery to Novo, Nordisk, or its R&D Center at 60 Sylvan on our Waltham Mega Campus.

We continue to execute and favorably resolve our development and redevelopment pipeline. From 4Q25 to 3Q26, the pipeline has shrunk by more than 50 percent, from 3.6 million square feet to 1.6 million square feet. This included three major accomplishments during 3Q26, including the following.

First, we delivered 529,000 square feet of development and redevelopment space. It was 84 percent occupied and will generate $40 million of annual net operating income. Second, we entered into a contract to sell most of our remaining investment in our development project at 421 Park Drive and the Fenway with a 4Q26 anticipated closing date. And third, with respect to our 311 Arsenal Street project of Watertown, we've executed leases of 67,000 square feet and 101,000 square feet of leases are under negotiation, primarily with advanced technology tenants, which has allowed us to pivot to a lower cost advanced technology execution and will reduce future construction needs by approximately $220 million over the next few years. As of 3Q26, we have 906,000 square feet of development and redevelopment projects under construction and expected to stabilize through 2028, which are 77% leased or negotiating.

In addition, we have 667,000 square feet primarily related to two projects for which we are evaluating the business and financial strategy. The first is 40 Sylvan Road, which is located in our Walton Mega Campus. We continue to believe this project would be attractive to advanced technology tenants that may find the campus, as well as certain elements of the building, attractive and may not require a conversion to lab. The second is 3000 Minuteman Road, which is located in our Andover mega campus. The campus is very attractive to advanced technology tenants as evidenced by the 160,000 square foot lease we executed for an adjacent building on this campus in 2Q26.

If we complete significant advanced technology leases, we may place all or some of these spaces into the operating pool, which may reduce operating occupancy in the near term, but more importantly, will reduce our future capital needs and generate near-term revenue upon delivery. We continue to make very good progress in raising capital, with $1.7 billion completed since June 30, including the $1 billion junior subordinated notes offering completed in August. The 7.25% junior subordinated notes offering had several important benefits, including the following four key features.

First, the rating agencies ascribe 50% equity credit to the notes, which will help us achieve our 2026 leverage goal. Second, it provided an implied cost of equity capital superior to the cost of issuing common equity as well as non-core stabilized operating asset sales.

Third, it reduces our 2026 target for asset sales and near-term reliance on joint ventures. And fourth, it represents a fixed cost of capital for at least five years with significant flexibility to refinance thereafter. We are highly focused on and expect to meet our $1.9 billion midpoint for dispositions and sales of partial interest. Our team is making good progress with $717 million completed, including $242 million of non-core and land dispositions and a $475 million sale of a partial interest related to our Campus Point mega campus. In addition, we have $355 million under contract and subject to non-refundable deposits, an additional $1.5 billion of dispositions and sales of partial interest with signed letters of intent or in late-stage negotiations.

Included in the $1.5 billion of pending transactions is one large joint venture for which we are actively engaged. The aggregate sum of the completed and pending transactions is $2.6 billion, which exceeds the midpoint of our 2026 guidance by approximately $720 million, which may provide us the opportunity to potentially close certain transactions in 2026 but defer the capital into 2027.

There are three key points on the campus point joint venture transaction I'd like to highlight. First, Alexander will control and consolidate the joint venture. Second, the joint venture contains a waterfall distribution model that shifts distributions over time. But at a minimum, we expect the joint venture to make distributions to our new partner equivalent to at least 5.5% of their initial $475 million contribution in year one and beyond. And third, our partner has a put right exercisable after seven years, and we may settle that amount in cash or shares of common stock at our election.

In connection with our disposition program, we did recognize impairments of real estate of $638 million during the quarter, of which substantially all of this amount is related to developments in process, land, or properties that were laboratory conversion opportunities. The two largest impairments made up 75% of the total balance and included the following.

First, we are under contract to sell to an institutional user substantially all our remaining space at our 421 Park Drive development project located in the Fenway. This project was acquired in January 2021 and was under construction. As a result of the expected sale, this removes the overhang on lease-up of this project, and the buyer will take on the cost to complete the interior lab improvements, which we estimate to be approximately $136 million. And second, this relates to a four-building office project located in our Palo Alto sub-market, which was acquired in January 2022 with a business plan to convert the buildings for laboratory use. This market has subsequently had limited demand for life science tenants, and we now expect to sell these assets rather than go forward with the redevelopment.

Looking forward, we have real estate assets under consideration for potential disposition in 2027 that may have estimated market values below their respective carrying values. These assets remain as health for use assets as of 3Q26 and remain recoverable under probability-weighted recovery analysis, and accordingly have not been impaired due to a variety of factors necessary to designate them as health for sale, including the lack of a final decision to proceed, as well as our current estimation that it is unlikely that we will complete these sales within the next 12 months. We could have impairments over the next couple of quarters if these types of assets subsequently meet the accounting requirements for held-for-sale designation as we refine our approach, make final decisions to proceed, obtain the necessary approvals, and commence the disposition marketing process.

We continue to have a strong and flexible balance sheet. Our corporate credit ratings rank in the top 20% of all publicly traded U. S. REITs. We have tremendous liquidity of $4.6 billion as of 3Q26, and we recently extended our $5 billion unsecured senior line of credit to 2032, providing additional significant flexibility. We continue to have the longest average remaining debt maturity among all S&P 500 REITs with an average term of 11.6 years, and we remain committed to meeting our leverage goal for 4Q26 of 5.6 to 6.2 times on a net debt to annualized adjusted EBITDA basis.

Over the intermediate term beyond 2026, we would like to be around mid-five times for leverage. We tighten the range of our guidance for 2026 FFO per share diluted as adjusted with no changes to the midpoint of $6.40. Key moving pieces underlying our 2026 guidance included a reduction of 10 million realized investment gains and slightly later timing on expected dispositions and sales of partial interest.

Our earnings release contains several key considerations that could have an impact on our results beyond 2026, which are highlighted on pages six and seven. Three key important takeaways from those pages to highlight.

First, we expect temporary pressure on occupancy in the first half of 2027, which includes the impact of the 1.4 million square feet of key lease expirations, which are expected to have downtime ranging from 9 to 24 months on average, with expiring rent of $101 million, and the potential for tenant winddowns. Based upon our current outlook and considering typical lag times between lease execution and delivery, we expect to see average occupancy growth in 2028.

Second, we expect same property performance to improve from both 2026 to 2027 and from 2027 to 2028, although we still expect 27 to be negative driven by occupancy. And then third, we continue to prioritize capital spending with high incremental returns, including costs to meet the market and lease up vacant space. And accordingly, we expect construction spending related to our operating assets to comprise a significant component of next year's construction forecast. forecast. We continue to refine our capital funding plan for 2027 and we expect to have access to the same funding tools used in 2026, including non-core and land dispositions, sales of partial interest, and other cost-effective capital. We also expect to continue to manage our leverage and other credit metrics carefully.

We continue to focus on the execution of the steps for our path forward that we established on our investor day. Our seasoned and best-in-class team remains disciplined and committed to making forward progress, including maintaining our strong balance sheet, solid lease volumes, reducing capital needs where it makes sense, procuring cost-efficient sources of capital, effectively managing G&A, and focusing on our highly differentiated mega-campus strategy. We believe these steps put us in a great position to be highly successful.

Now I'll turn it back to Joel.

Thanks, Mark. Operator, please open it up for questions.

Yeah. Hi, Jim. Mark. So, yeah, there's a 5.5% that's in place for at least the first several years. There are steps in that over time. And as I said, there is a put mechanism that's intended that if exercised would allow the investor to get to a certain IRR that they're targeting.

Thank you. And the second question kind of related as regards the other joint ventures you're working on hoping to close or negotiate at the end of the year, will that have a similar structure to you, imagine, a PUD and some sort of minimum? I'm just curious how the structuring of that is looking at this point. That is a structure that, you know, we're looking to potentially replicate, but the other joint venture that I did mention that we're actively engaged on right now is different than the Campus Point structure. All right.

Yeah. Hi, Farrell. So that is an estimate at this point. these situations are generally really hard to predict. We do go through and diligently underwrite each and every tenant. A lot of these tenants have milestones coming up, which, you know, will dictate whether or not they're able to raise capital. So certainly once we know that a tenant is vacating. The deferred rent gets written off. So, you know, it gets written off when they move out. They hit the occupancy rule. So, this is really our best guess at this point as to what happens next year. The other thing I would mention here is, you know, the run rate for 2026 has a similar number in there, you know, 30 to 35 million.

So, we're not, they shouldn't necessarily result in incremental dilution to next year because we're really just seeing we think we'll have a similar type of hit to the economics next year as we've had this year. Yeah.

So, Farrell, this is Joel. One other thing that – or a couple things to keep in mind. Since the kind of bear market, which followed the historic bull run and the COVID run-up, More and more funders of companies, certainly on the private side and sometimes on the public side, have sought to combine or merge companies, which historically they did, but the pace at which they've done it over the past handful of years has been much more pronounced. And I think we've had one case where a tenant, after we underwrote them, ended up taking on venture debt, and they were essentially almost put out of business or were put out of business, this goes back a handful of years, by the debt being called by a lender who was kind of not a traditional venture debt provider and just felt that the matters going on with the company were such that they triggered the debt without even breaching the covenant.

So we've seen things in this, I don't know if you call it cycle or just episodic period, that are different than past practice. So we're trying to be conservative here. But thank you.

And I just also wanted to ask about the progress that you've made in your 2027 key expirations now with the 22% under negotiation, which was essentially at zero in the last quarter, so definitely making progress there. if you could give a little bit more on the profile of that leasing. Is this any of this renewal or net new leasing and any economics or expected downtime relative to your underwriting as you're going through those negotiations?

Yeah. So I think I mentioned in my kind of prepared remarks, if you look at the 1.37 million square feet that's rolling that are, you know, move outs with downtime, a bunch of that, like, for example, in San Diego is Bristol Myers leaving space to go into their new building. That amount, the 1.37 is fully, you know, move out, and we now have over 60% in active tenant, some in late stage and some in early stage, but with specific tenants. So I think that's a really good sign for us at this stage to have that many specific situations under discussion or negotiation, I should say.

Yeah. Hey, Ronald. Yeah, you're right. That was the estimate that we had given off of our 2Q earnings call, $1.15 billion to $1.65 billion. We expect to be able to refine that number over the next, you know, five weeks here as we get prepared here for Investor Day. So I would say stay tuned. We'll have a better number in early December.

The one thing I can certainly tell you is we expect a big chunk of that to be targeted towards the operating portfolio, and a lot of that is stuff that's either leased or under negotiation. But, again, we'll have a better number here soon.

I don't think I can say at this point, Ronald.

Yeah, sure. Yeah, no, the joint venture is treated as permanent equity, Ronald. So there, you know, there is a put mechanism, there is a call option that Alexandria will hold, which really strategically is important to us because it allows us to control our destiny there long term on a campus that we really like, but in the meantime, get a very effective or efficient cost of capital, particularly in your term at the 5.5%.

Hey, this is Peter. This is Peter. Sorry, I'm a little under the weather, so my voice is bad. There is no guarantee, just to be clear. You had stated that it was guaranteed. That is not true. Thank you. Got it. Thank you so much.

Hey, this is Peter. I'll take this one. You know, in past conferences I've been talking about, I thought our Tier 1 core assets would still have a five handle. I think that's getting pressured by rates. But I would say that things like Campus Point and other high quality would still have that threshold. but I would say that our overall better assets would trade with a six cap handle on it.

And then we've got some good workhorse assets that could trade anywhere between seven and a half and eight and a half. The market is a specific or it is specifically tied to markets. The big three markets tend to have lower cap rates, and markets like Seattle tend to have lower cap rates. Those markets are typically looked at by institutional investors as favorable markets, and historically we've done well there, but there are other markets that are more suburban that typically have 100 to 150 basis points spread, not because of the quality of the assets or the tenancy, but just because of the location.

Hopefully that's helpful.

That's correct, Seth. We would continue to consolidate the Campus Point Joint Mentor, and the EBITDA would stay on balance sheet or stay on the income statement and include it in the leverage computation.

Yeah. Hi, John. Yeah. Clearly, in order to have occupancy growth in 2028, we're going to have to continue at a very healthy pace of leasing, particularly leasing of vacant space. So we, you know, this quarter was a really a strong quarter in that regard. We had 450,000 square feet leased. It was, you know, previously vacant, second highest in company history. So we're going to need to continue the focus there. And, you know, we're working hard every day to continue that. So that's going to be key.

Well, I think it's fair to say, John, much like our early tenants, Google, and then during the heydays of, you know, the last technology boom, companies like Stripe and Pinterest, Those folks came to us because of our ability to put, you know, creative spaces together that allowed them to retain and recruit great talent and having the infrastructure for what they needed. and we're finding the same thing with a whole range of advanced technology clients. There have been a whole series of articles about those coming to our campuses for both the infrastructure and what's offered on the campus. So, you know, it kind of speaks for itself.

And this is Peter. If I could add, it's not only it benefits Alexandria as a wider tenant base to lease from, But it is also going to take a lot of the current supply that was built and marketed as lab. It probably shouldn't have been. And we're definitely seeing that. So it's been serendipitous for that segment to really start to have a bunch of funding coming into it and a lot of companies being created because lab buildings are perfect for what they need. And we're definitely seeing that as a source to chew up some of the supply.

Yeah. Now, one footnote to what Peter said, which I think is generally true, is some of those buildings are really true zombie buildings built in locations that, you know, people just don't want to go to. So there's got to be, you know, some other adaptive reuse. But in general, if well located, they would be recipients of that demand.

Yeah, Tony, maybe I'll talk about it in the context of, you know, I would say non-core and land. There's definitely a combination of both of those in the 355. A big chunk of that, as an example, is the 421 park. So that will have, you know, basically no cap rate. The bigger chunk, you know, they'll call it 1.5 billion, a pending, a big chunk of that is a joint venture that we're working on. And I would apologize, I have to ask you to stay tuned on the economics since we are, you know, currently in advance discussions on that deal Okay And then going back to the discussion on the construction spending for next year if I look at the remaining spend on the few developments that you have underway, I think it's about a half a billion dollars.

Yeah. No, there'll definitely be some capitalized costs for the portfolio, right? So, capped interest, capitalized operating expenses is an example. in this year's construction forecast. We've got, let's see, we've got $210 million of the $1.75 billion is future, you know, call it land. Almost all of that is capitalization. So there will be some of that as well.

You know, TBD, what that ends up being. But you're right, Tony, in that it suggests that there is a large amount that is going to be tied into the operating portfolio for, you know, leasing a vacant space. So that will definitely be the majority.

Hey, Rich. It's Peter. congratulations on expanding your vocabulary. The, yeah, look, the 30% quarter over quarter from 4Q to 1Q was definitely an anomaly. I had never seen it jump like that. And then last quarter, you may recall, it went up another 10%. That is something that we would see. So a 5% move down is really kind of normal. So, you know, it usually goes from flat to plus or minus, you know, 7 or so percent.

So I think, at least for now, there was probably some pent-up demand that came out, boosted, you know, from 4Q to 1Q, a little bit more leaked out after that, and I think we're probably in a stable situation at this point. That's my best guess.

Yeah, hi, Rich. It will certainly be on the menu. I mean, I think what we've done and what we expect to do this year is a little unique. You know, we did one on Omega Campus, as we talked about. I think the other JV that we're working on will be a little different than that. So likely something having to do with multiple assets, multiple types of assets. So it could be core and non-core.

So certainly, as you mentioned, future JVs would be on the menu for next year, as well as some land and some non-core assets that, you know, we weren't able to get done this year. We'll certainly be on the menu for next year to resolve a big chunk of the capital plan.

or will there always be a need for some sort of non mega campus sort of assets in and around the portfolio yeah I think there'll always be a need rich this is Joel remember too we have a variety of core but non mega campus assets a good example is the Lilly building in the seaport so we will continue to have a balance I think you know you may see it move up to 85% maybe at a height 90% but I wouldn't expect it would be, you know, 95 or 100 at any point.

Well, I think you have to remember and go to the pie chart in our supplement. Remember, this niche, and it is a niche, and life science sector is made up of a whole bunch of sectors, subsectors, if you will, and Hallie on past calls have gone through the health of each. Each kind of are different for different reasons. Obviously, public biotech with marketed products or approved products is one that would be normally pretty steady. It's the public biotech in the clinic but without immediate data as value inflection milestone is where the pinch point has been. private has been historically pretty stable it's gone through ups and downs but it's pretty stable institutional has come roaring back in an important way life science product services tools etc has been continually strong so I think you know don't get lost in public biotech as as you know the entire sector pharma is obviously chunky but steady so that's what I would say but we are expecting to see, based on the best we can tell from our discussions, negotiations, fourth quarter should see an upswing in public biotech for the first time in quite a number of quarters.

And I think that's, you know, irrespective of Alexandria, I think that's healthy for the industry.

Well, it's a combination. We do have one large move out in Tech Square, which is coming to the end of a lease, actually a big pharma that has consolidated elsewhere years before, and that's an example of a backfill. But we are seeing activity. Here we are, what, a year and a half away, or a year and a quarter, whatever it may be, and we're starting to see some activity there so our thoughts are, you know, maybe more positive than they were, say, 3, 6, 9, 12 months ago.

Yeah, that's the big one, yeah, or the big combination, yes. Yeah.

Well, yeah, you can't kind of make a judgment like that because each space is so unique, And, you know, where you have built-out lab space, obviously that's not necessarily a target for advanced technology. But where you may have office space or you have shelf space in a building that has, you know, robust infrastructure and it's on a campus, that certainly could be 311 Arsenal, which Mark alluded to on our Watertown Arsenal on the Charles Campus is a good example of that. So they're not interchangeable one-for-one by any means.

Well, again, it's space by space, but generally, yes, because oftentimes these are extremely well-capitalized companies that are prepared to put in significant tenant improvements on their own. And they, you know, a little bit like pharma. Pharma generally puts in a huge amount of capex on their own. So we would expect, yes, less downtime.

Yeah, hi, Dylan. So for the balance of this year, you know, we got the Campus Point joint venture done. The other joint venture we're working on for 2026 is not that. I mentioned earlier, it'll probably be a combination of multiple assets, core and non-core, not necessarily mega-campus driven.

Next year is a little bit of a TBD. I certainly, as I said at the outset of the call, the structure we used for the campus point joint venture would be something that we would consider doing again. But it's a little too early to kind of comment on what the mix of partial interest sales might look like. But I would say we're certainly open to both, but we're also very focused on, you know, finding the most cost-efficient capital in this environment.

Yeah, well, certainly this quarter was a strong number. Last quarter was actually a pretty strong number as well in terms of new leasing. So, we have really seen that the last two quarters. We, I think, combined over the last two quarters, we've leased over or almost 800,000 square feet of that type of leasing. And we've started to accumulate a large amount of space that's been leased that hasn't yet hit the occupancy rolls.

And we're seeing that there can be a significant delay between when those leases get executed and when they get delivered, right? If you look today, we've got, you know, 1.3 million square feet. That, you know, on average, that stuff's not delivering until June of next year. So our commentary for 28 was really based upon market conditions today and what we think we can get done, understanding that in many cases, a lot of these spaces will have a fair amount of a lag between when we lease and when we deliver.

Thank you very much, everybody, and look forward to meeting everybody on Investor Day. Thanks so much.